西妥昔单抗联合DF化疗方案对食管癌的治疗作用研究

Therapeutic Effect of Cetuximab Combined with DF Chemotherapy on Esophageal Cancer

目的探讨对食管癌患者选择西妥昔单抗+DF化疗方案治疗后获得的临床效果。方法选择该院2015年4月—2017年1月收治的90例食管癌患者作为实验对象;数字奇偶法分组后探究每组食管癌治疗方案;比照组(45例):采用DF化疗方案展开疾病治疗;实验组(45例):采用西妥昔单抗+DF化疗方案展开疾病治疗;最终就两组食管癌患者治疗结果展开对比。结果实验组食管癌患者治疗前SCC水平为(2.60±0.79)μg/L,CEA水平为(3.02±0.85)μg/L;比照组治疗前SCC水平为(2.61±0.82)μg/L,CEA水平为(3.00±0.81)μg/L;实验组治疗后SCC水平为(0.68±0.23)μg/L,CEA水平为(1.65±0.57)μg/L;比照组治疗后SCC水平为(0.89±0.29)μg/L,CEA水平为(2.06±0.62)μg/L;最终发现,治疗前,实验组食管癌患者SCC水平以及CEA水平同比照组比较差异无统计学意义(t=0.058 9,0.114 2,P>0.05);治疗后,实验组食管癌患者SCC水平以及CEA水平降低程度明显,差异有统计学意义(t=3.805 9,3.265 6,P<0.05);实验组食管癌患者1年生存率(86.67%)以及2年生存率(55.56%)均高于比照组(66.67%、31.11%)明显,差异有统计学意义(χ^2=5.031 1,5.475 1,P<0.05)。结论食管癌患者于临床接受西妥昔单抗+DF化疗方案治疗后,对于SCC水平以及CEA水平的降低,1年生存率以及2年生存率的提升,效果显著,最终对于食管癌患者康复状态的提升,奠定基础。

Objective To investigate the clinical effects of treatment with cetuximab + DF chemotherapy in patients with esophageal cancer. Methods 90 patients with esophageal cancer admitted to our hospital from April 2015 to January 2017 were selected as subjects. The digital parity method was used to investigate the treatment plan of each group of esophageal cancer. The comparison group (45 cases): DF chemotherapy was used for disease treatment;experimental group (45 cases): treatment with cetuximab + DF chemotherapy for disease treatment;finally, the treatment results of two groups of esophageal cancer patients were compared. Results The preoperative SCC level in the experimental group was (2.60±0.79)μg/L, and the CEA level was (3.02±0.85)μg/L. The SCC level before the treatment group was (2.61±0.82)μg/L, CEA level (3.00±0.81)μg/L;the SCC level in the experimental group was (0.68±0.23)μg/L, the CEA level was (1.65±0.57)μg/L;the SCC level after the treatment group was (0.89±0.29)μg/L, CEA level was (2.06±0.62)μg/L;finally, before treatment, the SCC level and CEA level of the esophageal cancer patients in the experimental group were not significantly different (t=0.058 9, 0.114 2,P>0.05). After treatment, the SCC level and CEA level of patients with esophageal cancer in the experimental group were significantly decreased,the difference w asstatistically significant(t=3.805 9, 3.265 6,P<0.05);the 1-year survival rate (86.67%) and the 2-year survival rate (55.56%) of the esophageal cancer patients in the experimental group, were higher than the comparison group (66.67% and 31.11%),the difference wa sstatistically significant(χ^2=5.031 1, 5.475 1,P<0.05). Conclusion After treatment with cetuximab + DF chemotherapy, patients with esophageal cancer have a significant effect on the reduction of SCC level and CEA level, 1-year survival rate and 2-year survival rate, and finally laid the foundation for the recovery status of patients with esophageal cancer.